| dbo:abstract
|
- Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:medlinePlus
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 12403 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:legalAu
| |
| dbp:legalCa
|
- Rx-only / Schedule D (en)
|
| dbp:legalEu
| |
| dbp:legalStatus
| |
| dbp:legalUk
| |
| dbp:legalUs
| |
| dbp:licenceEu
| |
| dbp:mabType
| |
| dbp:medlineplus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyAu
| |
| dbp:pronounce
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:source
| |
| dbp:synonyms
|
- KRN-23, KRN23, burosumab-twza (en)
|
| dbp:target
| |
| dbp:tradename
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:medication
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
